CL2018001334A1 - Anticuerpos y conjugados anticuerpo-fármaco anti-5t4. - Google Patents

Anticuerpos y conjugados anticuerpo-fármaco anti-5t4.

Info

Publication number
CL2018001334A1
CL2018001334A1 CL2018001334A CL2018001334A CL2018001334A1 CL 2018001334 A1 CL2018001334 A1 CL 2018001334A1 CL 2018001334 A CL2018001334 A CL 2018001334A CL 2018001334 A CL2018001334 A CL 2018001334A CL 2018001334 A1 CL2018001334 A1 CL 2018001334A1
Authority
CL
Chile
Prior art keywords
antibodies
antibody
drug conjugates
antigen
affinity
Prior art date
Application number
CL2018001334A
Other languages
English (en)
Inventor
Gerardus Joseph Andreas Ariaans
Rudy Gerardus Elisabeth Coumans
Der Lee Miranda Maria Cornelia Van
Jan Schouten
Marion Blomenrohr
Patrick Gerhard Groothuis
Original Assignee
Synthon Biopharmaceuticals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Biopharmaceuticals Bv filed Critical Synthon Biopharmaceuticals Bv
Publication of CL2018001334A1 publication Critical patent/CL2018001334A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON ANTICUERPOS CONTRA EL ANTÍGENO ONCOFETAL 5T4 HUMANO Y LOS CONJUGADOS ANTICUERPO-FÁRMACO CORRESPONDIENTES ADECUADOS PARA SU ESTUDIO EN ENSAYOS CLÍNICOS. LOS ANTICUERPOS PRESENTAN REACTIVIDAD CRUZADA PARA SERES HUMANOS Y MONOS CYNOMOLGUS, Y EXHIBEN UNA AFINIDAD CON ANTÍGENO 5T4 HUMANO EN EL MISMO ORDEN DE MAGNITUD QUE SU AFINIDAD CON ANTÍGENO 5T4 DE MONO CYNOMOLGUS. LA INVENCIÓN TAMBIÉN SE RELACIONA CON EL USO DE LOS ANTICUERPOS Y CONJUGADOS ANTICUERPO-FÁRMACO CORRESPONDIENTES EN EL TRATAMIENTO DE TUMORES SÓLIDOS Y NEOPLASIAS HEMATOLÓGICAS.
CL2018001334A 2015-11-24 2018-05-17 Anticuerpos y conjugados anticuerpo-fármaco anti-5t4. CL2018001334A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15195978 2015-11-24
EP16191272 2016-09-29

Publications (1)

Publication Number Publication Date
CL2018001334A1 true CL2018001334A1 (es) 2018-12-21

Family

ID=57406227

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001334A CL2018001334A1 (es) 2015-11-24 2018-05-17 Anticuerpos y conjugados anticuerpo-fármaco anti-5t4.

Country Status (23)

Country Link
US (2) US11008400B2 (es)
EP (1) EP3380122B1 (es)
JP (1) JP6914956B2 (es)
KR (1) KR20180083425A (es)
CN (1) CN108348608B (es)
AU (1) AU2016358854B2 (es)
BR (1) BR112018010394A8 (es)
CA (1) CA3005294A1 (es)
CL (1) CL2018001334A1 (es)
CY (1) CY1124456T1 (es)
DK (1) DK3380122T3 (es)
ES (1) ES2889398T3 (es)
HR (1) HRP20211280T1 (es)
HU (1) HUE055482T2 (es)
LT (1) LT3380122T (es)
MX (1) MX2018006372A (es)
MY (1) MY187325A (es)
PL (1) PL3380122T3 (es)
RU (1) RU2736720C2 (es)
SG (1) SG11201803692PA (es)
TW (1) TWI744261B (es)
WO (1) WO2017089447A1 (es)
ZA (1) ZA201802584B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913977TA (en) * 2014-05-22 2020-03-30 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
CN110831976A (zh) 2017-05-23 2020-02-21 斯索恩生物制药有限公司 用于制备抗体-药物缀合物的双重缀合方法
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
CN108187065B (zh) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
CR20250347A (es) 2018-03-12 2025-09-23 Genmab As ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-0463)
CN117843795A (zh) * 2019-03-11 2024-04-09 凯惠科技发展(上海)有限公司 一种含半胱氨酸的抗体、药物偶联物及其应用
CN111499746B (zh) * 2020-04-28 2020-11-24 优睿赛思(武汉)生物科技有限公司 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用
AU2023220523A1 (en) * 2022-02-21 2024-09-12 Lepu Biopharma Co., Ltd. Anti-5t4 antibodies and uses thereof
CN120112312A (zh) * 2022-10-18 2025-06-06 Tubulis 股份有限公司 新型抗-tpbg抗体和基于其的抗体-药物偶联物、其治疗方法及用途
AU2024232498A1 (en) * 2023-03-08 2025-08-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-5t4 antibodies and uses thereof
CN121002067A (zh) * 2023-04-03 2025-11-21 非同（成都）生物科技有限公司 抗5t4抗体及其应用
KR20260016944A (ko) * 2023-05-22 2026-02-04 시스트이뮨, 인코포레이티드 항-클라우딘18.2 항체 및 이의 제조 및 사용 방법
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68923027D1 (de) 1988-03-04 1995-07-20 Cancer Res Campaign Tech Antigene.
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
CA2558399C (en) 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US20060088522A1 (en) 2004-09-10 2006-04-27 Wyeth Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates
ES2579805T3 (es) * 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
NZ596295A (en) * 2006-03-10 2013-01-25 Wyeth Corp Anti-5T4 antibodies and uses thereof
CA2956934C (en) * 2010-04-21 2019-07-09 Syntarga B.V. Novel conjugates of cc-1065 analogs and bifunctional linkers
SG10201605401WA (en) * 2011-04-01 2016-08-30 Wyeth Llc Antibody-drug conjugates
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
SG10201913977TA (en) * 2014-05-22 2020-03-30 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
US11008057B2 (en) * 2015-10-22 2021-05-18 Komatsu Ltd. Track link and link mounted part
CN110831976A (zh) * 2017-05-23 2020-02-21 斯索恩生物制药有限公司 用于制备抗体-药物缀合物的双重缀合方法

Also Published As

Publication number Publication date
JP6914956B2 (ja) 2021-08-04
ES2889398T3 (es) 2022-01-12
HUE055482T2 (hu) 2021-11-29
US20210317231A1 (en) 2021-10-14
EP3380122B1 (en) 2021-06-02
RU2736720C2 (ru) 2020-11-19
US20190194346A1 (en) 2019-06-27
AU2016358854B2 (en) 2023-02-02
TWI744261B (zh) 2021-11-01
WO2017089447A1 (en) 2017-06-01
ZA201802584B (en) 2022-12-21
KR20180083425A (ko) 2018-07-20
CN108348608A (zh) 2018-07-31
US11008400B2 (en) 2021-05-18
LT3380122T (lt) 2021-10-11
BR112018010394A2 (pt) 2018-11-21
SG11201803692PA (en) 2018-06-28
MY187325A (en) 2021-09-22
CY1124456T1 (el) 2022-07-22
EP3380122A1 (en) 2018-10-03
US11584801B2 (en) 2023-02-21
AU2016358854A1 (en) 2018-05-10
CN108348608B (zh) 2022-02-08
BR112018010394A8 (pt) 2019-02-26
CA3005294A1 (en) 2017-06-01
MX2018006372A (es) 2018-09-05
JP2018538368A (ja) 2018-12-27
PL3380122T3 (pl) 2021-12-13
HRP20211280T1 (hr) 2021-11-12
RU2018122629A3 (es) 2020-04-27
DK3380122T3 (da) 2021-07-05
TW201731879A (zh) 2017-09-16
RU2018122629A (ru) 2019-12-26

Similar Documents

Publication Publication Date Title
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
CL2019003266A1 (es) Anticuerpos anti-sirpalfa.
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
CL2019001745A1 (es) Conjugados anticuerpo droga para ablacion de celulas madre hematopoyeticas.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
BR112017011111A2 (pt) conjugados de pirrolobenzodiazepina-anticorpo
UY35964A (es) Anticuerpos humanos para pd?1
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
BR112015027309A2 (pt) anticorpo, composição, método de tratamento e uso de um anticorpo
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
CL2017000311A1 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
MX2025003354A (es) Anticuerpos que se unen a 5t4
BR112015030356A2 (pt) métodos de tratamento de uma taupatia